Skip to main content
Close
Home
Society of Hospital Medicine
Presented by Society of Hospital Medicine
Home
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Sharon Worcester

Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.

News

On improving DLBCL outcomes, single-agent regimens fall short

Author:
Sharon Worcester
Publish date: October 20, 2021

Single-agent regimens are most likely not efficient enough to substantially improve outcomes of DLBCL patients.

  • Read More

News

‘Unprecedented’ 3-year sustained survival with lung cancer combo treatment

Author:
Sharon Worcester
Publish date: October 4, 2021

The overall survival benefit with durvalumab plus etoposide and cisplatin/carboplatin versus EP alone for the...

  • Read More

News

COVID boosters help protect blood cancer patients, but some still vulnerable

Author:
Sharon Worcester
Publish date: September 30, 2021

Some patients with hematologic malignancies who are seronegative after a full course of COVID-19 vaccination may benefit from a booster.

  • Read More

News

Response to preop immunotherapy predicts survival in early NSCLC

Author:
Sharon Worcester
Publish date: September 30, 2021

For each 10% increase of residual viable tumor, risk of death was increased 64% and risk of recurrence was increased 71%.

  • Read More

News

Studies confirm survival benefit with postchemoradiotherapy consolidation in NSCLC

Author:
Sharon Worcester
Publish date: September 29, 2021

The findings show a progression-free survival benefit in patients who underwent concurrent or sequential chemoradiotherapy giving insight to real-...

  • Read More

News

Study supports chemotherapy with immunotherapy for some never-smokers with lung cancer

Author:
Sharon Worcester
Publish date: September 28, 2021

Although patients with PD-L1 expression below 50% derive clear benefit from combination versus single-agent therapy, treatment selection overall...

  • Read More

News

First-line bevacizumab-osimertinib disappoint in EGFR-mutant NSCLC

Author:
Sharon Worcester
Publish date: September 24, 2021

The combination provided no added progression-free survival benefit over osimertinib monotherapy for EGFR-mutated nonsquamous NSCLC, but raised...

  • Read More

News

Most community-based oncologists skip biomarker testing

Author:
Sharon Worcester
Publish date: September 21, 2021

Survey shows that 48% of community clinicians use biomarker testing to guide treatment decisions, compared with 73% of academic clinicians.

  • Read More

News

Breast density associated with increased invasive breast cancer risk after age 65

Author:
Sharon Worcester
Publish date: September 17, 2021

Breast density and life expectancy should be considered together when making decisions about mammography screening in older women.

  • Read More

News

Combo treatment for NSCLC with brain metastases extends survival by two years for some

Author:
Sharon Worcester
Publish date: September 15, 2021

The progression-free survival findings are similar to those of a related trial that also showed improved outcomes with pembrolizumab plus...

  • Read More

News

COVID vaccine response in patients with solid tumors

Author:
Sharon Worcester
Publish date: September 9, 2021

Among cancer patients with solid tumors, response the COVID-19 vaccine 6 months after receiving a second dose...

  • Read More

News

FDA approves neoadjuvant pembro for triple-negative breast cancer

Author:
Sharon Worcester
Publish date: August 4, 2021

It is the first immunotherapy regimen to be approved for high-risk early-stage triple negative breast cancer.

  • Read More

News

FDA warns of higher death risk with Pepaxto in multiple myeloma

Author:
Sharon Worcester
Publish date: July 28, 2021

The FDA also hinted at “a future public meeting to discuss the safety findings and explore the continued marketing of Pepaxto,” which has a price...

  • Read More

News

Many pandemic-driven changes to cancer clinical trials should remain

Author:
Sharon Worcester
Publish date: July 28, 2021

Improvements included more efficient study enrollment through secure electronic platforms, direct shipment of...

  • Read More

News

Latest FDA pembrolizumab approval expands label to cutaneous SCCs

Author:
Sharon Worcester
Publish date: July 13, 2021

The objective response rate in 54 patients with locally advanced disease was 50%, including a complete response rate of 17% and a partial response...

  • Read More

Pages

  • « first
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »
An Official Publication of the Society of Hospital Medicine

Society of Hospital Medicine
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Copyright  © 2023 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Menu Close